BiotechTube
Mapreg

Mapreg

Paris, France· Est.
mapreg.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $1.2M

Overview

Mapreg is a private, clinical-stage biotech pioneering a novel class of CNS therapeutics called neuroplastogens, which aim to restore neuroplasticity at the core of neurons. Its lead asset, MAP4343, has received Orphan Drug Designation for Spinal Cord Injury and is positioned for Phase 2b/3 trials in Treatment-Resistant Depression (TRD). The company is backed by prestigious scientific founders, including Lasker Awardee Pr. Etienne Baulieu, and has raised approximately €20 million in equity, supplemented by significant non-dilutive grants from entities like the US Army and EUREKA.

Major Depressive DisorderTreatment-Resistant DepressionSpinal Cord InjuryTraumatic Brain Injury

Technology Platform

Neuroplastogen platform targeting the intracellular MAP2 protein to re-drive neuroplasticity from within neurons, based on the discovery of neurosteroid (pregnenolone) binding to microtubule-associated proteins.

Funding History

1
Total raised:$1.2M
Seed$1.2M

Opportunities

The primary opportunity is to establish a first-in-class, disease-modifying treatment for severe depression, a multi-billion dollar market with high unmet need.
The Orphan Drug path in Spinal Cord Injury offers a faster regulatory route and premium pricing in an untapped market.
The platform's potential extends to other neurodegenerative and psychiatric conditions.

Risk Factors

High risk of clinical failure in upcoming Phase 2b/3 trials for a novel mechanism.
Dependency on securing additional financing and a major pharmaceutical partnership to fund late-stage development.
Intense competition in the CNS therapeutic landscape from both established and novel agents.

Competitive Landscape

Mapreg competes in the CNS space against large pharma, biotechs developing psychedelics, ketamine derivatives, and other novel mechanisms (e.g., NMDA, GABA modulation). Its differentiation lies in its unique intracellular target (MAP2) and neuroplastogen mechanism, aiming for durable remission by addressing synaptic pathology directly, unlike symptomatic neurotransmitter modulators.

More companies in Small Molecule Drugs →More companies in France →